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Introduction
Amiodarone hydrochloride is a benzofu-
ran derivative used for the treatment of severe
arrhythmias1. It was originally marketed as anti-
anginal agent for its potent vasodilatatory effect.
Subsequently, it was employed in the treatment of
atrial and ventricular arrhythmias. Amiodarone is
widely used for cardioversion of atrial fibrillation
and maintenance of normal sinus rhythm. 
Amiodarone distributes extensively in several tis-
sues, because of its high protein- and lipid-bond. A
prolonged, although variable, period of administra-
tion with a loading dose (600 mg-1 g/day) is nec-
essary before the adipose storage is saturated.
Subsequently, lower dosages (200-400 mg/day)
are usually sufficient. Extensive accumulation of
amiodarone, especially in adipose tissue, explains
its prolonged elimination, which ranges from 13 to
103 days. 
Side effects of amiodarone involved cardiovascular
system, lungs, thyroid, eyes, nervous system, liver
and gastrointestinal tract1, 2. Incidence and charac-
teristics of side effects are reported in Table 1. 
Side effects may be idiosyncratic or dose-related
(dependent on the daily dosage, the duration of the
therapy or the total cumulative dosage).
Side effects can appear months or years after the
beginning of therapy. Furthermore, side effects can
last weeks or months after amiodarone discontinu-
ation. We report a case of rosacea induced by amio-
darone. 
Case report
A 59-year-old man was admitted to our
Institute because of a typical papulo-pustular rosa-
cea. The patient stated that he was affected by essen-
tial hypertension and ventricular arrhythmia, for
which he was under therapy with amiodarone (400
mg/day since six months). The patient also stated that
the dermatitis had appeared two months before. 
Dermatological examination showed no signs of
photosensitivity as well as hyperpigmentation.
General physical examination did not reveal any-
thing pathological, except for the known mild
essential hypertension. Laboratory examinations
were within normal ranges or negative.
Bacteriological examinations of three pustules
were negative; the search for Demodex folliculo-
rum was also negative. 
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SUMMARY
Amiodarone is an anti-arrhythmic
agent. Its most common cutaneous
side effects are photosensitivity
and hyperpigmentation.
Furthermore, amiodarone rarely causes allergic rash,
exfoliative dermatitis, toxic epidermal necrolysis, leuco-
cytoclastic vasculitis, pseudoporphyria, linear IgA bul-
lous dermatosis, vegetating iododerma and myxoedema.
An increased susceptibility to the development of basal
cell carcinomas was also reported. Only one case of
rosacea due to amiodarone was reported so far. 
We describe a case of papulo-pustular rosacea which
appeared four months after the beginning of the thera-
py with amiodarone. The disease did not improve
despite several topical and oral therapies. However, it
improved within six weeks after amiodarone discontin-
uation and completely cleared up within three months.
Follow-up at one year was negative. 
Key words: Amiodarone, rosacea.
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The patient was treated with 15% azelaic acid gel
(two applications/day) and oral azithromycin (500
mg/day for three consecutive days/week) for eight
weeks. Two months later, the patient was exam-
ined; however, his rosacea had worsened.
Topical 0.75% metronidazole (two applica-
tions/day) and oral doxycycline (100 mg/day) were
therefore prescribed for two months. Two months
later, the clinical picture was unchanged. A biopsy
was performed. Histopathological examination
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Table 1. Systemic side effects of amiodarone1, 2
TOXICITY INCIDENCE SIDE EFFECTS FEATURES TREATMENT
Cardiovascular
~28% Hypotension During i.v. administration Dosage reduction
2-3% Heart failure Dosage reduction
<1% Torsade de pointes
Idiosyncratic reaction,
especially when a
concomitant hypokalemia
is present or in association
with other antiarrhythmic
agents (quinidine)
Beta-blockers
and/or cardioversion
<0.3% Worsening of arrhythmia Discontinuation
Pulmonary 2-17% Eosinophilic alveolitis Usually before one year
of therapy
Discontinuation and
systemic corticosteroids
Thyroid
~2% Hyperthyroidism
2-10% Hypothyroidism
Ocular
70-100% Corneal maculae
Caused by
intracytoplasmatic
deposits of amiodarone,
especially during
long-term therapy
Complete resolution
in 3 to 7 months after
amiodarone
discontinuation
50-60% Lens opacities
Caused by
intracytoplasmatic
deposits of amiodarone,
especially during
long-term therapy
Complete resolution
in 3 to 7 months after
amiodarone
withdrawal
<2%
Retinopathy
(macular degeneration),
optic neuritis, optic neuropathy
Decreased or blurred vision.
Rare progression to
permanent blindness
Discontinuation
Neurological 20-40%
Tremor, ataxia, sleep
abnormalities, dizziness,
fatigue, headache,
peripheral neuropathy
Dose-related, usually
during the first weeks
of therapy
Dosage reduction
Gastrointestinal ~25%
Nausea, loss of appetite,
taste abnormalities,
abdominal pain, vomiting
During the first weeks
of therapy, probably
dose-related
Dosage reduction and/or
drug intake with meals
Hepatic 4-25%
Abnormalities in liver
function tests
(increased aminotransferase
and alkaline phosphatase levels,
hyperammonemia,
hyperbilirubinemia,
hypoalbuminemia)
Asymptomatic Dosage reduction
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confirmed the clinical diagnosis of rosacea. At the
same time, the patient began to complain of
blurred vision.
Because of the well-known ocular toxicity of
amiodarone, the latter was stopped. Approximately
six weeks after discontinuation of amiodarone,
rosacea spontaneously improved; within three
months, complete remission of the dermatitis,
without specific treatment, was observed. A one
year follow-up was negative.
Discussion
The most common side effect of amio-
darone on the skin is photosensitivity. Its incidence
ranges from 5 to 20% of patients; however, in
some studies higher percentages (30 to 75%) were
reported3. Photosensitivity occurs after exposure
to both UVA4 and UVB5 and is not related to the
skin phototype. It is possible that this photosensi-
tivity is dependent by the total cumulative dosage
of the drug (approximately 40 g: this amount can
be reached in approximately four months of thera-
py). Photosensitivity gradually disappears in 4 to 12
months after amiodarone discontinuation. A
histopathological study of sun-exposed skin con-
firmed a higher concentration of amiodarone com-
plexes when compared with non-sun-exposed skin3.
By means of electron microscopy, an accumulation
of intracytoplasmic inclusions of phospholipids
combined with amiodarone or its metabolites was
demonstrated. Other authors suggested that these
inclusions could be lipofuscins6. Sunscreens are
useful, but the avoidance of sun exposure is the
main way to prevent or minimize photosensitivity.
The second most common cutaneous side effect by
amiodarone is hyperpigmentation. It occurs in
almost 8% of patients, consists in a blue-grey or
purplish discoloration and is more visible in sun-
exposed areas, especially the face7, 8.
This pigmentation is more common in patients
with a previous history of photosensitivity, but a
true correlation with sun sensitivity was not
demonstrated. Among the patients with hyperpig-
mentation, a predominance of skin phototype was
observed. This pigmentation seems to be related to
the daily dosage and duration of amiodarone9. It
appears after 12 to 24 months of therapy, which is
approximately the time needed to reach a cumula-
tive dose of 160 g. The pathogenesis of this pig-
mentation is unknown5, 6, 10.
Pigmentation usually improves within 12 months
after amiodarone withdrawal11, 12, although a per-
sisting (more than two years) pigmentation was
also reported. In the latter case, Q-switched ruby
laser represents an effective treatment13.
An increased susceptibility to the development of
basal cell carcinomas was also suspected14-16. 
Leucocytoclastic vasculitis is another rare side
effect of amiodarone17.
It is dose-dependent and improves spontaneously
with a reduction of the dosage. Furthermore, amio-
darone was responsible for isolated cases of vege-
tating iododerma18, which appears after approxi-
mately two years of therapy and can be successful-
ly treated with cyclosporine19, pseudoporphyria20,
linear IgA bullous dermatosis21, toxic epidermal
necrolysis22, exfoliative dermatitis23 and facial
myxedema7.
To our knowledge, only one case of amiodarone-
induced rosacea was reported so far24. Rosacea
occurred in a 68-year-old man who was treated
with amiodarone for two years. The disease was
characterized by teleangectasias, rhinophyma, and
multiple, large, confluent chalazia. 
We believe that, also in our patient, amiodarone
played a pathogenetic role in the development of
rosacea for several reasons:  
a) the appearance of rosacea four months after the
beginning of the therapy with amiodarone; 
b) the resistance of the disease to multiple topical
and oral treatments; 
c) the marked improvement of rosacea six weeks
after amiodarone discontinuation; 
d) the complete remission of the dermatitis three
months later, and 
e) the lack of relapses one year later. 
These factors are highly suggestive for the exis-
tence of a correlation between amiodarone and the
appearance of rosacea.
However, as Rei(er et al.24, we are not able to sug-
gest pathogenetic hypotheses.
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